Search
Powered By HealthLine
Health Tools
 Depression Basics
 Antidepressant Drug Info
 Depression Q&A
 Depression Support Groups
 Depression Related Disorders
Featured Conditions
 Depression
 Anxiety
 Sleep
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Valtrex

[Valacyclovir]


Clinical Pharmacology
CLINICAL PHARMACOLOGY

After oral administration, valacyclovir hydrochloride is rapidly absorbed from the gastrointestinal tract and nearly completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism.

Pharmacokinetics

Text Continues Below



The pharmacokinetics of valacyclovir and acyclovir after oral administration of VALTREX have been investigated in 14 volunteer studies involving 283 adults.

Absorption and Bioavailability

The absolute bioavailability of acyclovir after administration of VALTREX is 54.5% ± 9.1% as determined following a 1-gram oral dose of VALTREX and a 350-mg intravenous acyclovir dose to 12 healthy volunteers. Acyclovir bioavailability from the administration of VALTREX is not altered by administration with food (30 minutes after an 873 Kcal breakfast, which included 51 grams of fat).

There was a lack of dose proportionality in acyclovir maximum concentration (Cmax) and area under the acyclovir concentration-time curve (AUC) after single-dose administration of 100 mg,
250 mg, 500 mg, 750 mg, and 1 gram of VALTREX to 8 healthy volunteers. The mean Cmax ( SD) was 0.83 ( 0.14), 2.15 ( 0.50), 3.28 (± 0.83), 4.17 ( 1.14), and 5.65 ( 2.37) mcg/mL, respectively; and the mean AUC ( SD) was 2.28 ( 0.40), 5.76 ( 0.60), 11.59 ( 1.79), 14.11 (± 3.54), and 19.52 ( 6.04) hr•mcg/mL, respectively.

There was also a lack of dose proportionality in acyclovir Cmax and AUC after the multiple-dose administration of 250 mg, 500 mg, and 1 gram of VALTREX administered 4 times daily for 11 days in parallel groups of 8 healthy volunteers. The mean Cmax ( SD) was 2.11 (± 0.33), 3.69 ( 0.87), and 4.96 ( 0.64) mcg/mL, respectively, and the mean AUC ( SD) was 5.66 ( 1.09), 9.88 ( 2.01), and 15.70 ( 2.27) hr•mcg/mL, respectively. There is no accumulation of acyclovir after the administration of valacyclovir at the recommended dosage regimens in healthy volunteers with normal renal function. Distribution: The binding of valacyclovir to human plasma proteins ranged from 13.5% to 17.9%.

Page:  1 | 2 | 3 | 4 | 5 | Next >>







HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire